TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26623405
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron + 8 mg dexamethasone (Group OD)
Study: 23993109
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (bemiparin) for 10 days at a prophylactic dose, early ambulation, and compression therapy for 3 months
Study: 23993109
Drug: Early ambulation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early ambulation and compression therapy alone
Study: 18194979
Drug: Valsartan (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80-160 mg/d)
Study: 18194979
Drug: Metoprolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50-100 mg/d)
Study: 8970342
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 micrograms twice a day)
Study: 1306041
Drug: Lignocaine 3
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 3 ml 1%
Study: 1306041
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline 3 ml
Study: 21288803
Drug: Pentavac(®) (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavac(®) (new vaccine)
Study: 3303244
Drug: Ramified amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramified amino acids (24 g in a 750 ml solution) infused daily for 10 days
Study: 3303244
Drug: Sorbitol (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (5% solution, 750 ml) infused daily for 10 days
Study: 28776922
Drug: Subcutaneous exendin
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous exendin (9-39) injection
Study: 16464887
Drug: On-line haemodiafiltration
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-line haemodiafiltration with acetate (3 mmol/l)
Study: 10610746
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone 400 mg/day for 1 month before and 200 mg/day for 2 months after cardioversion
Study: 10610746
Drug: Oral diltiazem
Normalized name: diltiazem Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diltiazem 180 mg/day for 1 month before and 2 months after cardioversion and potassium infusion
Study: 10610746
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral diltiazem 180 mg/day for 1 month before and 2 months after cardioversion)
Study: 3529953
Drug: Regular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aspirin (325 mg)
Study: 29432648
Drug: Pilocarpine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (5 mg, 10 drops orally, three times daily for 12 weeks)
Study: 29432648
Drug: Artificial saliva
Normalized name: ARTIFICIAL SALIVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial saliva (10 drops orally, three times daily for 12 weeks)
Study: 26678717
Drug: Neuromuscular taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular taping (NMT) and standard physical therapy programme (SPTP)
Study: 26678717
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy programme (SPTP)
Study: 19887674
Drug: NS-398 (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS-398 (selective COX-2 inhibitor) added in vitro
Study: 15817865
Drug: Home-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based therapy with RUTF
Study: 1445513
Drug: Diuretic (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (hydrochlorothiazide 25 mg or 50 mg plus amiloride 2.5 mg or 5 mg daily)
Study: 1445513
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker (atenolol 50 mg daily)
Study: 4061343
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg zinc added to daily vitamin and mineral supplements)
Study: 4061343
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar daily vitamin and mineral supplements without zinc)
Study: 24849434
Drug: DC-CIK immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC-CIK immunotherapy combined with TACE
Study: 22984155
Drug: Inhaled fentanyl
Normalized name: fentanyl Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fentanyl 25 µg
Study: 22984155
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl 25 µg
Study: 22984155
Drug: Inhaled fentanyl
Normalized name: fentanyl Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fentanyl (50 to 300 µg)
Study: 20819419
Drug: Intraperitoneal instillation
Normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal instillation of 2 mg/kg ropivacaine
Study: 18281049
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for 3 months
Study: 18281049
Drug: Ethinyl estradiol-cyproterone
Normalized name: cyproterone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyl estradiol-cyproterone acetate (EE/CPA) treatment for 3 months
Study: 10598759
Drug: Topical 5-aminolaevulinic
Normalized name: methyl 5-aminolevulinate Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-aminolaevulinic acid photodynamic therapy (ALA-PDT)
Study: 7564784
Drug: IFN‐alpha (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha (6 MU three times weekly for 12‐24 weeks)
Study: 1940881
Drug: Alpha interferon
Normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha interferon (5-6 million units daily)
Study: 30346560
Drug: Modified S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified S-1 treatment (reduced initial dose of S-1 by ≥ 1 level compared with the standard dose)
Study: 26176649
Drug: Hot compresses
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot compresses (40°C) applied to the lumbar area for 5 hours daily for 2 weeks
Study: 22963328
Drug: Multimodal training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal training intervention (MTI) consisting of daily endurance and twice-a-week strength training
Study: 19343362
Drug: Coconut and
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL LIQUID [Hand Sanitizer Coconut and Lime 3oz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut and anise spray
Study: 19343362
Drug: Permethrin 0.43%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 0.43% lotion
Study: 12423713
Drug: Metoprolol (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (high-dose, 1-year course)
Study: 12423713
Drug: Carvedilol (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (high-dose, 1-year course)
Study: 8584309
Drug: Combined diphtheria-tetanus
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined diphtheria-tetanus vaccine administered at 3, 5, and 12 months of age.
Study: 29071332
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral administration of ticagrelor, 180mg
Study: 29071332
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (chewing and standard oral administration)
Study: 17466465
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention designed to decrease sexual and injection risk behaviors, delivered in six sessions.
Study: 14984453
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.15 U/kg body weight)
Study: 14984453
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (0.15 U/kg body weight)
Study: 11157184
Drug: AR-R15896AR 250
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-R15896AR 250 mg loading dose
Study: 11157184
Drug: AR-R15896AR 120
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-R15896AR 120 mg maintenance dose
Study: 27364771
Drug: Veledimex (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veledimex (oral activator ligand) administered in Labrasol slurry and F-22 capsule formulations
Study: 27364771
Drug: Veledimex (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veledimex (oral activator ligand) administered once daily for 14 days
Study: 27364771
Drug: Veledimex (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veledimex (overall treatment)
Study: 24250307
Drug: Diet regimen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet regimen, exercise training, and medical treatment for two months
Study: 18344107
Drug: Sustained-release acetaminophen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release acetaminophen, 1300 mg orally q8h for 11 doses
Study: 11878530
Drug: 4% gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% gelatin solution (Gelofusine) 15 ml kg(‐1) i.v. (colloid group)
Study: 9181155
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg hyperbaric lidocaine 5%
Study: 9181155
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg hyperbaric lidocaine 5%
Study: 9181155
Drug: Both dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosage groups (75 mg and 100 mg)
Study: 3596336
Drug: Ranitidine 2
Normalized name: ranitidine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 2 X 150 mg per day
Study: 30526588
Drug: Two rounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two rounds of mass drug administration (MDA) with dihydroartemisinin‐piperaquine and single low‐dose primaquine, administered 4 weeks apart in May‐June 2016.
Study: 15618781
Drug: Terlipressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1 mg)
Study: 11875582
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (10 mmol) infusion
Study: 10448830
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 23‐35 mg/kg/day, t.i.d.
Study: 2149388
Drug: cilazapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (2.5 to 5.0 mg)
Study: 2149388
Drug: hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (25 to 50 mg)
Study: 364285
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vincristine and prednisone with streptonigrin
Study: 364285
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vincristine and prednisone with cyclophosphamide
Study: 30554751
Drug: Home-based screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based screening for abnormal vaginal flora and urinary tract infections; treatment with oral clindamycin (300 mg twice daily for 5 days) for abnormal vaginal flora and cefixime (400 mg once daily for 3 days) or oral nitrofurantoin (100 mg twice daily for 7 days) for urinary tract infections.
Study: 30554751
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received standard antenatal and postnatal care without the specific screening and treatment for infections.
Study: 30554751
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of abnormal vaginal flora and urinary tract infections in the intervention group.
Study: 28072802
Drug: 10% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sodium chloride solution added to lidocaine, triamcinolone, and hyaluronidase (hypertonic group)
Study: 28072802
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional transforaminal epidural steroid injections)
Study: 19270861
Drug: Warmed contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed contrast material (Omnipaque [Iohexol] 350 mg I/mL at 37 degrees C)
Study: 19270861
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature contrast material (Omnipaque [Iohexol] 350 mg I/mL at 24 degrees C)
Study: 15465995
Drug: Low-dose omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose omega-3 fatty acids
Study: 11465517
Drug: Mirtazapine treatment
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine treatment after a 4-day washout period
Study: 182347
Drug: Estrogen treatments
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatments (Premarin, Provera, Provera and diethylstilbestrol, diethylstilbestrol alone)
Study: 19657295
Drug: 1.5 mg.kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg.kg BW caffeine
Study: 19657295
Drug: 3 mg.kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg.kg BW caffeine
Study: 17244923
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 15 mg x kg(‐1) before heparin and before protamine injection
Study: 14746622
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% used twice daily
Study: 14746622
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (reactive treatment)
Study: 11719310
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nocturnal oxygen therapy)
Study: 25633497
Drug: Oral reduced
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral reduced L-glutathione (GSH) 65 mg · kg(‐1) · day(‐1) divided into 3 doses per day for 6 months
Study: 25633497
Drug: Oral reduced
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral reduced L-glutathione (GSH)
Study: 20184615
Drug: Psychotropic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medication (mostly pimozide)
Study: 14570168
Drug: Oral temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral temperature
Study: 10199876
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) - 8 mg/min
Study: 7774991
Drug: Metoprolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (40 mg)
Study: 25803679
Drug: 10 J/cm²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 J/cm² IPL treatment
Study: 25803679
Drug: 13 J/cm²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 J/cm² IPL treatment
Study: 25803679
Drug: Both 10J
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 10J and 13J IPL treatment
Study: 24105697
Drug: Magnesium (50
Normalized name: magnesium gluconate 27 mg magnesium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (50 mg/kg bolus followed by 50 mg/kg infusion for 3 hours)
Study: 27461675
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Paclitaxel 175 mg/m² on day 1 and Carboplatin 450 mg on day 2 (PC)
Study: 27461675
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Docetaxel and Cisplatin 75 mg/m² each on day 1 and Ifosfamide 2 g/m² on day 1-3 along with Mesna (docetaxel-ifosfamide-cisplatin)
Study: 25131839
Drug: Curcumin extract
Normalized name: Curcumin Extract 300 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin extract (630mg thrice daily)
Study: 25131839
Drug: Placebo (thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (thrice daily)
Study: 23303874
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg daily)
Study: 15678413
Drug: Ordered categorical
Normalized name: Orderable Drug Form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordered categorical doses of antidepressants
Study: 12670818
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg.kg(‐1) iv (maximum dose 8 mg)
Study: 27435791
Drug: nifuratel-500 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifuratel-500 (500 mg nifuratel, intravaginal, 10 days)
Study: 27435791
Drug: nifuratel-250 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifuratel-250 (250 mg nifuratel, intravaginal, 10 days)
Study: 16095462
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 10 mg/h + morphine 0.16 mg/h (Group L)
Study: 16095462
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 16 mg/h + morphine 0.16 mg/h (Group H)
Study: 16095462
Drug: Placebo PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PCA morphine (Group PL)
Study: 7791061
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% apraclonidine, one drop before and after surgery
Study: 7791061
Drug: Sustained-release acetazolamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release acetazolamide, 500 mg
Study: 2152944
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro best regimen (IVBR), a three-drug combination of proved efficacy in SCLC, administered as secondary therapy to patients with partial or no responses after primary therapy.
Study: 2152944
Drug: Empiric combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric combination of vincristine-doxorubicin-cyclophosphamide, administered as secondary therapy when DST data were unavailable.
Study: 2152944
Drug: Primary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary therapy with etoposide and cisplatin, followed by restaging after 12 weeks.
Study: 2152944
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro drug sensitivity testing (DST) data used to select chemotherapy.
Study: 2152944
Drug: IVBR as
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVBR as secondary therapy.
Study: 359121
Drug: 5FU infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5FU infusion with Mitomycin-C
Study: 359121
Drug: 5FU infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5FU infusion with Methyl-CCNU
Study: 29408760
Drug: Zataria multiflora
Normalized name: Reynoutria multiflora root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zataria multiflora 5 mg/kg/day
Study: 29408760
Drug: Zataria multiflora
Normalized name: Reynoutria multiflora root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zataria multiflora 10 mg/kg/day
Study: 22354664
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2) at 3 ATA for 10 consecutive days
Study: 19818077
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg once daily (od) alone
Study: 19818077
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg od combined with simplified bladder training
Study: 19818077
Drug: Solifenacin 10
Normalized name: solifenacin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 10 mg od (after dose increase)
Study: 17605004
Drug: Tramadol 200
Normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 200 mg
Study: 17605004
Drug: Tramadol 400
Normalized name: tramadol hydrochloride 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 400 mg
Study: 17605004
Drug: Naloxone 0.1
Normalized name: naloxone 0.18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.1 mg IM
Study: 17605004
Drug: Naloxone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.2 mg IM
Study: 17605004
Drug: Morphine 15
Normalized name: morphine 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 15 mg IM
Study: 17605004
Drug: Morphine 30
Normalized name: ethylmorphine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 30 mg IM
Study: 10359389
Drug: Metformin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (in obese patients)
Study: 8530606
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sandostatin LAR 20 mg
Study: 8530606
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sandostatin LAR 30 mg
Study: 8530606
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sandostatin LAR (3, 6, 9, or 12 mg)
Study: 1779103
Drug: Gel‐Larmes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel‐Larmes
Study: 6123069
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Dihydergot (0.25 mg i.v.) and etilefrine (15 mg p.o.)
Study: 6123069
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Dihydergot (2 mg) and etilefrine (20 mg)
Study: 6114845
Drug: Etilefrine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine (20 mg)
Study: 6123069
Drug: Dihydergot (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydergot (2 mg)
Study: 28826740
Drug: Parnaparin sodium
Normalized name: parnaparin sodium
DrugBank: Parnaparin (DB09260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin sodium (low-molecular weight heparin) for the whole cycle